Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 1005-1011

  Wada, M ^a   Yamamoto, M ^a   Ryuge, S ^a   Nagashima, Y ^a   Hayashi, N ^a   Maki, S ^a   Otani, S ^a   Katono, K ^a   Takakura, A ^a   Yanaihara, T ^a   Igawa, S ^a   Yokoba, M ^a   Mitsufuji, H ^a   Kubota, M ^a   Katagiri, M ^a   Masuda, N ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

EGFR mutation; Non small cell lung cancer; Oral cytotoxic agent; Phase II study; S 1; Second line chemotherapy

Indexed keywords

FLUOROURACIL; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPIPHORA; FEMALE; FEVER; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INNER EAR DISEASE; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECEPTOR GENE; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXONIC ACID; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84859787729     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1795-5     Document Type: Article

References (21)

1. Govindan R, Morgenzstern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J (2011) Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:790-795
2. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597 (Pubitemid 41079796)
3. Hashizume T, Nakada Y (2009) S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer. Gan To Kagaku Ryoho 36:963-967
4. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000-2005 (Pubitemid 29399250)
5. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85:939-943 (Pubitemid 33015993)
6. Matsushima E, Yoshida K, Kitamura R (1997) Determination of S-1 (combined drug of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 691:95-104 (Pubitemid 27168843)
7. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18:317-323 (Pubitemid 46323100)
8. Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Janne PA, Nakagawa K (2009) Addition of S-1 to the epidermal growth factor receptor inhibitor geWtinib overcomes geWtinib resistance in non-small cell lung cancer cell lines with met ampliWcation. Clin Cancer Res 15:907-913
9. Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K (2008) Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor geWtinib in non-small cell lung cancer cell lines: role of geWtinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 7:599-606 (Pubitemid 351492458)
10. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
11. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'rourke M, Levitan N, Gressot L, ffincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
13. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557 (Pubitemid 26276346)
14. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009 (Pubitemid 23267702)
15. Shiroyama T, Komuta K, Imamura F, Hirashima T, Kijima T, Tachibana I, Kawase I (2011) Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer 74:85-88
16. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, Danenberg PV (1984) Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44:4144-4150 (Pubitemid 14041649)
17. Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, Fujiwara Y, Matsuo K, Ouchida M, Takata M, Kiura K, Date H (2007) Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 25:3952-3957 (Pubitemid 47477273)
18. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748-755 (Pubitemid 17132408)
19. Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, Uchiyama Y, Takeuchi Y, Okazawa M, Sakakibara H (2009) A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 64:1181-1185
20. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, Sugita M (2005) Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93:884-889 (Pubitemid 41487013)
21. Wilkinson DS, Tlsty TD, Hanas RJ (1975) The inhibition of ribosomal rna synthesis and maturation in novikoff hepatoma cells by 5-fluorouridine. Cancer Res 35:3014-3020